Patents by Inventor Ronald M. Kim
Ronald M. Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220202829Abstract: Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.Type: ApplicationFiled: November 12, 2021Publication date: June 30, 2022Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani, Andrea S. Kim, Mayssa Attar, Ronald Bradford, Rhett M. Schiffman
-
Publication number: 20220000844Abstract: Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.Type: ApplicationFiled: December 2, 2019Publication date: January 6, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Christopher J. Bungard, Helen Y. Chen, Jason M. Cox, Liangqin Guo, Michael J. Kelly, III, Ronald M. Kim, Mark E. Layton, Hong Liu, Jian Liu, Mehul F. Patel, James J. Perkins, Deping Wang, Walter Won, Younong Yu, Ting Zhang
-
Publication number: 20210309671Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, where-in R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.Type: ApplicationFiled: May 31, 2019Publication date: October 7, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Tao YU, Alan WHITEHEAD, Yili CHEN, Chunrui SUN, Zhiyong HU, Kake ZHAO, Ronald M. KIM, John A. McCAULEY
-
Patent number: 10968210Abstract: Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same.Type: GrantFiled: November 13, 2017Date of Patent: April 6, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Thomas J. Greshock, James Mulhearn, Anthony J. Roecker, Tianying Jian, Gang Zhou, Liangqin Guo, Walter Won, Ting Zhang, Rajan Anand, John E. Stelmach, Deping Wang, Ronald M. Kim, Mark E. Layton, Christopher S. Burgey, Philippe G. Nantermet
-
Publication number: 20200131167Abstract: Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same.Type: ApplicationFiled: November 13, 2017Publication date: April 30, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Thomas J. Greshock, James Mulhearn, Anthony J. Roecker, Tianying Jian, Gang Zhou, Liangqin Guo, Walter Won, Ting Zhang, Rajan Anand, John E. Stelmach, Deping Wang, Ronald M. Kim, Mark E. Layton, Christopher S. Burgey, Philippe G. Nantermet
-
Patent number: 10519147Abstract: Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same.Type: GrantFiled: December 15, 2016Date of Patent: December 31, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Thomas J. Greshock, James Mulhearn, Liangqin Guo, Ting Zhang, Deping Wang, Ronald M. Kim, Mark E. Layton, Michael J. Kelly, III, Rajan Anand, Philippe Nantermet, Tianying Jian, Anthony J. Roecker, Walter Won, Gang Zhou
-
Publication number: 20190233406Abstract: Disclosed are compounds of Formula A, or a salt thereof: wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.Type: ApplicationFiled: January 11, 2019Publication date: August 1, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Thomas J. Greshock, James Mulhearn, Junying Zheng, Ronald M. Kim, Ting Zhang, Anthony J. Roecker, Walter Won, Philippe Nantermet, Rajan Anand, Gang Zhou, Deping Wang, Liangqin Guo
-
Patent number: 10221167Abstract: Disclosed are compounds of Formula A, or a salt thereof: wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.Type: GrantFiled: December 14, 2016Date of Patent: March 5, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Thomas J. Greshock, James Mulhearn, Junying Zheng, Ronald M. Kim, Ting Zhang, Anthony J. Roecker, Walter Won, Philippe Nantermet, Rajan Anand, Gang Zhou, Deping Wang, Liangqin Guo
-
Publication number: 20180362518Abstract: Disclosed are compounds of Formula A, or a salt thereof, where Q, X, R1 and R2 are as defined herein, which compounds have properties for inhibiting Na 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain (acute, post-operative, neuropathic), or cough or itch disorders using the same.Type: ApplicationFiled: December 15, 2016Publication date: December 20, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Thomas J. Greshock, James Mulhearn, Liangqin Guo, Ting Zhang, Deping Wang, Ronald M. Kim, Mark E. Layton, Michael J. Kelly, III, Rajan Anand, Philippe Nantermet, Tianying Jian, Anthony J. Roecker, Walter Won, Gang Zhou
-
Patent number: 10011595Abstract: The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 14, 2015Date of Patent: July 3, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Ronald M. Kim, Scott D. Kuduk, Nigel Liverton, Gang Zhou
-
Patent number: 9938276Abstract: The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 14, 2015Date of Patent: April 10, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Ronald M. Kim, Scott D. Kuduk, Nigel Liverton, Gang Zhou
-
Publication number: 20170355692Abstract: The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: December 14, 2015Publication date: December 14, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Ronald M. Kim, Scott D. Kuduk, Nigel Liverton, Gang Zhou
-
Patent number: 9834554Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.Type: GrantFiled: December 16, 2014Date of Patent: December 5, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Jian Liu, Ronald M. Kim, Joseph Kozlowski, Deodialsingh Guiadeen, Arto D. Krikorian, Younong Yu
-
Publication number: 20170320874Abstract: The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: December 14, 2015Publication date: November 9, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Ronald M. Kim, Scott D. Kuduk, Nigel Liverton, Gang Zhou
-
Patent number: 9718828Abstract: Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.Type: GrantFiled: August 30, 2016Date of Patent: August 1, 2017Assignees: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B.V.Inventors: Adrianus Petrus Antonius De Man, Jan-Gerard Sterrenburg, Hans C. A. Raaijmakers, Allard Kaptein, Arthur A. Oubrie, Johannes Bernardus Maria Rewinkel, Christiaan Gerardus Johannes Maria Jans, Jacobus C. H. M. Wijkmans, Tjeerd A. Barf, Alan B. Cooper, Ronald M. Kim, Sobhana Babu Boga, Hugh Y. Zhu, Xiaolei Gao, Xin Yao, Rajan Anand, Hao Wu, Shilan Liu, Chundao Yang, Abdul-Basit Alhassan, James Wang, Younong Yu, Jian Liu, Henry M. Vaccaro
-
Publication number: 20170174674Abstract: Disclosed are compounds of Formula A, or a salt thereof: wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.Type: ApplicationFiled: December 14, 2016Publication date: June 22, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Thomas J. Greshock, James Mulhearn, Junying Zheng, Ronald M. Kim, Ting Zhang, Anthony J. Roecker, Walter Won, Philippe Nantermet, Rajan Anand, Gang Zhou, Deping Wang, Liangqin Guo
-
Patent number: 9637486Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.Type: GrantFiled: December 16, 2014Date of Patent: May 2, 2017Assignee: MERCK SHARP & DOHME CORP.Inventors: Jian Liu, Ronald M. Kim, Joseph Kozlowski, Arto D. Krikorian, Rajan Anand
-
Publication number: 20170008899Abstract: Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.Type: ApplicationFiled: August 30, 2016Publication date: January 12, 2017Applicants: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B.V.Inventors: ADRIANUS PETRUS ANTONIUS DE MAN, JAN-GERARD STERRENBURG, HANS C. A. RAAIJMAKERS, ALLARD KAPTEIN, ARTHUR A. OUBRIE, JOHANNES BERNARDUS MARI REWINKEL, CHRISTIAAN GERARDUS JOHANNES MARIA JANS, JACOBUS C.H.M. WIJKMANS, TJEERD A. BARF, ALAN B. COOPER, RONALD M. KIM, SOBHANA BABU BOGA, HUGH Y. ZHU, XIAOLEI GAO, XIN YAO, RAJAN ANAND, HAO WU, SHILAN LIU, CHUNDAO YANG, ABDUL-BASIT ALHASSAN, JAMES WANG, YOUNONG YU, JIAN LIU, HENRY M. VACCARO
-
Publication number: 20160326164Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof. Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.Type: ApplicationFiled: December 16, 2014Publication date: November 10, 2016Applicant: MERCK SHARP & DOHME CORP.Inventors: JIAN LIU, RONALD M. KIM, JOSEPH KOZLOWSKI, DEODIALSINGH GUIADEEN, ARTO D. KRIKORIAN, YOUNONG YU
-
Patent number: 9481682Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.Type: GrantFiled: January 22, 2014Date of Patent: November 1, 2016Assignee: MERCK SHARP & DOHME CORP.Inventors: Ronald M. Kim, Jian Liu, Xiaolei Gao, Sobhana Babu Boga, Deodialsingh Guiadeen, Joseph A. Kozlowski, Wensheng Yu, Rajan Anand, Younong Yu, Oleg B. Selyutin, Ying-Duo Gao, Hao Wu, Shilan Liu, Chundao Yang, Hongjian Wang